EFR3B

Across TCGA pan-cancer cohorts, EFR3B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EFR3B data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher EFR3B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EFR3B expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

LSCC, GBM, and LUAD are the cancer types where EFR3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	All	0.539	1.000	.014	5	view →
GBM	DFS	Tertile	All	0.799	0.624	.019	3	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.341	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

EFR3B–LSCC (DFS)

Open the LSCC breakdown →